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Abstract
Background: Many drug delivery systems are based on the ability of certain macrocyclic compounds – such as cyclodextrins
(CDs) – to act as molecular containers for pharmaceutical agents in water. Indeed b-CD and its derivatives have been widely
used in the formulation of hydrophobic pharmaceuticals despite their poor abilities to act as a molecular container (e.g.,
weak binding (Ka,10
4 M
21) and their challenges toward chemical functionalization. Cucurbit[n]urils (CB[n]) are a class of
molecular containers that bind to a variety of cationic and neutral species with high affinity (Ka.10
4 M
21) and therefore
show great promise as a drug delivery system.
Methodology: In this study we investigated the toxicology, uptake, and bioactivity of two cucurbit[n]urils (CB[5] and CB[7])
and three CB[n]-type containers (Pentamer 1, methyl hexamer 2, and phenyl hexamer 3). All five containers demonstrated
high cell tolerance at concentrations of up to 1 mM in cell lines originating from kidney, liver or blood tissue using assays for
metabolic activity and cytotoxicity. Furthermore, the CB[7] molecular container was efficiently internalized by macrophages
indicating their potential for the intracellular delivery of drugs. Bioactivity assays showed that the first-line tuberculosis drug,
ethambutol, was as efficient in treating mycobacteria infected macrophages when loaded into CB[7] as when given in the
unbound form. This result suggests that CB[7]-bound drug molecules can be released from the container to find their
intracellular target.
Conclusion: Our study reveals very low toxicity of five members of the cucurbit[n]uril family of nanocontainers. It
demonstrates the uptake of containers by cells and intracellular release of container-loaded drugs. These results provide
initial proof-of-concept towards the use of CB[n] molecular containers as an advanced drug delivery system.
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Introduction
The improvement of public health relies in large part upon the
discovery and approval of new drugs. Unfortunately, in recent
years only about 8% of compounds submitted for clinical
development are approved compared to nearly 14% ten years
ago [1]. Studies have shown that one major reason for this
decreased success rate is poor drug bioavailability [2]. Bioavail-
ability is defined as the rate and extent to which the active
ingredient in a drug formulation becomes available at the site of
necessary action [3]. Factors that influence drug bioavailability are
solubility, in vivo/in vitro stability, ability to cross internal
membranes, toxicity, distribution and/or metabolism among
other factors. Each aspect of drug bioavailability is key during
the drug discovery process [3], therefore if adequate solutions to
low bioavailability are not devised, further development of a drug
candidate is unlikely. Because more and more drug candidates are
failing to meet acceptable standards of bioavailability the number
of novel, commercially available drugs is decreasing, while the
funds invested in the drug discovery process are increasing [2]. For
this reason, extensive interest has turned towards the approach of
improving the bioavailability of drug candidates via the use of drug
delivery vehicles [2].
One approach to improve the bioavailability of drug candidates
is to non-covalently encapsulate them within molecular containers.
To date a number of classes of molecular containers (e.g.
dendrimers, cyclodextrins (CDs), and nanoparticles) have shown
promise in improving drug bioavailability. For example, dendri-
mers are globular structures that are composed of repeated
branches forming a hollow interior which allows for the
encapsulation of guest molecules. These globular complexes have
been utilized in cancer treatment, wound healing, and in the
prevention of HIV transmission [4,5,6]. Likewise, CDs, are a class
of macrocyclic molecular containers that have been extensively
studied for their use in drug delivery [7]. These compounds have
also been demonstrated to increase drug solubility in water and
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delivery systems may improve drug bioavailability by altering the
solubility of a drug in water, stability during storage or in vivo,
toxicity, side effects, drug resistance, absorption and also by
providing specific targeting options to specify distribution and thus
improve drug efficiency [2,9,10].
Over the past decade a new class of molecular containers known as
cucurbit[n]urils (CB[n]) have been studied intensively because their
intriguing recognition properties render them prime components for
academic applications including the development of chemical sensors
and molecular machines and also due to their potential to supplant
the cyclodextrins as an effective drug delivery system. For example,
CB[n] compounds are available in a variety of sizes (n=5, 6, 7, 8, 10)
[11] that span and exceed those available in the cyclodextrin series
(a-, b-, and c–CD; n=5, 6, 7). These CB[n] are readily synthesized
on a kilogram scale by the condensation reaction of glycoluril with
formaldehyde under acidic conditions [12]. CB[5], CB[6], CB[7],
and CB[8] are even commercially available. CB[n] compounds are
expected to be particularly advantageous in drug delivery studies
because they bind theirtargets strongly(generallyKa.10
4 M
21)b ya
combination of the hydrophobic effect and ion-dipole interactions
with the ureidyl C=O groups of the CB[n] portals [13,14,15]. Even
more importantly, the release of the guest may be triggered by a
variety of stimuli (e.g. pH, photochemistry, electrochemistry) [16].
The preclinical stage of drug discovery is an integral part of the
drug discovery process and is a necessary step in the development
of CB[n] type molecular containers as a novel drug delivery
system. This stage of the drug discovery process involves the
understanding of the candidate’s specific features such as the
ability to cross crucial membranes, metabolic stability and their
ability to pass a series of in vitro and in vivo toxicity screens to assess
safety in the human system [17,18]. Drug toxicology is a crucial
aspect of drug discovery because only about 1 out of 5,000
screened drugs are approved for medicinal use due to the fact that
most drugs fail toxicology assays conducted on animals [17].
Although the analysis of the chemical and biological significance of
container-drug complexes of CB[n]s with albendazole [19],
platinum-based anticancer drugs [20], Vitamin B(12) [21] and
antibiotics such as proflavine [22] have been reported, there is very
little information reported about the toxicology of the empty
CB[n] containers.
This paper focuses on providing a proof-of-principle for the use
of CB[n] and CB[n]-type molecular containers in drug delivery
applications. In particular, we performed a systematic investiga-
tion of the cytotoxicity of the CB[n]s. Thus, we demonstrated that
CB[5], CB[7], and 1–3 are well tolerated up to doses of 1 mM by
human kidney (HEK293), human hepatocyte (HepG2), and
murine macrophage (RAW264.7) cell lines as monitored via cell
cytotoxicity and metabolic activity assays. Furthermore, we show
that CB[7] complexes are well internalized by RAW264.7 and
transported to lysosomes. Finally, CB[7] can be efficiently loaded
with the anti-tuberculosis drug ethambutol (EMB) and be used for
treatment of macrophages infected with mycobacteria. Thus, here
we provide additional evidence that several members of the CB[n]
family are promising tools for drug delivery.
Results and Discussion
Structure and synthesis of CB[n] and CB[n]-type
compounds
We selected two CB[n] compounds, CB[5] and CB[7] (Fig. 1),
for this initial study because of their excellent solubility in water.
From the CB[n]-type compounds available in the Isaacs lab we
also selected acyclic glycoluril pentamer (1) and two hexamers (2
and 3). Compounds 1–3 retained the ability to bind strongly to
their targets but did so with faster kinetics due to their acyclic
structures [23,24]. In order to allow for the tracking of these CB[n]
molecular containers inside cells we synthesized compounds 4 [25]
and 5. Compounds 4 and 5 contain fluorescein or Alexa Fluor 555
dyes covalently attached to spermidine and adamantaneamine
subunits that resulted in tight non-covalent binding to CB[n]-type
compounds.
Toxicology assays of containers using HEK 293 and RAW
264.7 cell lines
One of the major problems faced during the drug discovery
process is toxicity. Therefore, there is a significant emphasis on
preclinical toxicity screening predominantly through cytotoxicity
assays [26,27]. As a first step toward establishing the potential of
CB[n] in drug delivery studies we decided to quantify the toxicity
of CB[n] and CB[n] type containers in cellular assays. Here we use
two complementary assays to analyze cytotoxicity: an MTS
(CellTiter 96 AQueous KitH) assay that measures cellular
metabolism, and the AK (ToxilightHBioAssay Kit) assay that
measures cell death via the release of the cytosolic enzyme
adenylate kinase into the supernatant. Both assays were used with
three different cell lines. Two of these cell lines, the HEK293 and
HepG2 cells, are commonly used in drug toxicity studies.
HEK293, a human kidney cell line, is used to assess the effect of
the drug candidate on the renal system and HepG2, a human
Figure 1. Structures of the five containers. CB7, CB5, Pentamer (1),
Me-Hexamer (2), and Ph- Hexamer (3) and FITC (4) and Alexa555 (5)
conjugates.
doi:10.1371/journal.pone.0010514.g001
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where drugs are metabolized. Camptothecin, erythromycin,
erythromycin estolate and all five containers were used in both
MTS and AK assays conducted on the HEK293, HepG2, and
RAW264.7 cell lines. Erythromycin is a commercially available
drug widely used to treat bacterial infections. Erythromycin
estolate, however, is a derivate with high toxicity [28]. Erythro-
mycin, with an EC50 value of 594 (6194) mM is significantly less
toxic compared to erythromycin estolate, which has an EC50 of
109 (67) mM [28]. These two drugs were chosen specifically to
serve as a point of comparison for the levels of cytotoxicity
resulting from the containers. Camptothecin served as a positive
control since it is an anticancer drug that targets and inhibits
topoisomerase I during cell division and thus induces cell death
[29,30,31]. Hence, the use of camptothecin resulted in greater cell
death is seen in RAW264.7 cells which double every 11 h [32] and
less cell death is observed in HEK293 cells which replicate
approximately every 24–36 h [33]. Camptothecin was not used for
HepG2 cells because these cells replicate only approximately every
48 h [34], thus, making camptothecin an ineffective death inducer.
Distilled water was used for HepG2 cell lysis instead.
The MTS and AK assays for all three cell lines were conducted
after two days of incubation with the containers at concentrations
of 10 mM, 100 mM, and 1 mM. Relative absorbance and
luminescence data was normalized to percent cell viability
(MTS) and death (AK). MTS assay for HEK293 cells indicated
that camptothecin treatment resulted in approximately 59%
decrease in cell viability. Erythromycin, at the highest concentra-
tion of 1 mM, produced only a slight reduction in metabolic
activity (84% viability) while erythromycin estolate induced an
<25 fold decrease (4% viability). In sharp contrast containers
CB[7], CB[5], and 1–3 at 1 mM dose resulted in 94, 96, 98, 100,
and 95% cell viabilities, respectively. Consequently, the cell
viability in the presence of the containers was comparable to that
of the untreated cell population and was significantly higher than
values for camptothecin, erythromycin and erythromycin estolate
(Figure 2A). These results suggest that all CB[n]-type containers
have good biocompatibility. As a complementary method to assess
biocompatibility we used the AK assay that measures cell death
through the release of adenylate kinase via a luminescence read-
out. The relative luminescence units (RLU) values were then
converted to relative cell death scale with camptothecin treatment
set at an arbitrary value of 100. Thus, the untreated cell
population indicated only 18% cell death and CB[7], CB[5], 1,
2, and 3 at a concentration of 1 mM resulted 9, 11, 10, 14 and
14% cell death. In contrast, at a concentration of 1 mM
erythromycin (82%) and erythromycin estolate (246%) presented
higher values of cell death comparable to the camptothecin treated
population (Figure 2B). Erythromycin estolate showed higher cell
death than even the camptothecin control.
Toxicity studies using the MTS and AK assays for the liver cell
line, HepG2, provided similar results to the HEK293 cells
(Figure 3A). The MTS assay for distilled water treated HepG2
population indicated a percent cell viability of 0.28% which was
comparable to that of erythromycin estolate at 1 mM (9% cell
viability). However, interestingly, the cell viability for erythromy-
cin at 1 mM indicated high survival at approximately 97%.
HepG2 treatment with 1 mM of CB[7], CB[5], 1, 2 and 3
resulted in 96, 97, 101, 102% and 96% cell viability respectively
compared to 100% viability in the untreated cell population
(Figure 3A). These results were also reflected in the AK assay.
Untreated cells indicated only 40% cell death while erythromycin
and erythromycin estolate treatment resulted in 76 and 103%
relative cell death. The containers CB[7], CB[5], 1, 2, and 3
provided values of 22, 24, 23, 17, and 4% death respectively in the
HepG2 cell line, in turn supporting the high survival values of the
MTS assay and untreated cell population (Figure 3B).
Mycobacterium tuberculosis, the causative agent of human tubercu-
losis (TB), results in 200–300 million cases annually leading to 2–3
million deaths. Despite the creation of a TB vaccine and
antibiotics, tuberculosis it is still an eminent problem across the
globe, primarily due to emerging drug resistance and the inability
of the vaccine to protect adults efficiently [35,36,37,38]. A novel
drug discovery system like the CB[n]-type molecular containers
could prove to aid in the improvement of TB treatments
[39,40,41]. Therefore, we started by assessing the toxicity of
CB[7], the most soluble of the containers in our study, using the
murine macrophage cell line, RAW264.7, via MTS and AK
assays. The MTS assay for the camptothecin treated RAW264.7
cell population resulted in a decrease in cell viability by
approximately 99%. At a 1 mM concentration, CB[7] was very
well tolerated in the cell line producing a 101% cell survival
(Figure 4A). The AK assay provided a complementary picture of
the biocompatibility of CB[7] with the untreated population cell
death equal to 38% whereas CB[7], at the highest dose of 1 mM,
resulted in an even lower 30% cell death (Figure 4B).
In conclusion, all three cell lines supported high doses of up to
1 mM of each container, while erythromycin and more so
erythromycin estolate resulted in high cell toxicity at this concentra-
tion. These results demonstrate that at least in these in vitro tests the
CB[n] compounds are as well tolerated by eukaryotic cells as the
widely prescribed antibiotic erythromycin. The low toxicity of the
CB[n] compares also favorably to other nanocontainers such as
liposomes, dendrimers and even cyclodextrins For example, after
only one day of treatment with 0.9 mM catanionic liposomes
approximately 80% cell death was observed in the macrophage cell
line RAW264.7 [42]. Similarly, cationic dendrimers induced a dose-
dependent cytotoxicity on RAW264.7 cells [43]. In addition, some
cationic polystyrene nanoparticles induced reactive oxygen depen-
dent cell death in RAW264.7 cells after only 16 h of incubation [44].
Cyclodextrins have been studied since the 1970s and they have
shown little toxicity in vivo. Nevertheless, they have the capacity to
extract cholesterol from eukaryotic membranes and create holes,
leading to direct cytotoxicity in vitro in studies using erythrocytes [45].
Thus our results indicate that all of the analyzed CB[n] containers are
promising drug-delivery vehicles at least in regard to their
cytotoxicity.
Uptake and localization of CB[7] using RAW 264.7 cells
Next the uptake and trafficking of fluorescently tagged CB[7] by
RAW264.7 cells was analyzed. Flow cytometry was used to
quantify the cellular uptake of CB[7]N4 using a dose titration assay
and a time course assay. Visual confirmation of uptake and
analysis of intracellular localization was conducted using CB[7]N5
through fluorescence microscopy.
The fluorescent CB[7]N4 and CB[7]N5 complexes used in these
experiments are held together by non-covalent interaction.
Accordingly, there is the possibility of an equilibrium between
the free and bound dye forms. It is known, however, that CB[7]
binds with high affinity to the adamantaneammonium ion subunit
of 5 (Ka=4.2610
12 M
21) and the butanediammonium ion
subunit of 4 (Ka=1.5610
5 M
21) [14,46]. At the millimolar
concentrations of CB[7]N4 and CB[7]N5 used in our experiments
we calculate that at least 90% of 4 and 99% of 5 are present as
their CB[7] complexes.
The dose-dependent uptake of the fluorescent CB[7]N4 was
characterized via flow cytometry using 3.2 and a 32 mMo f
CB[7]N4.C B [ 7 ] N4 was incubated with RAW264.7 cells for 20 min
Cucurbit[n]uril Nanocontainers
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f l u o r e s c e n c ei n t e n s i t y( M F I )o f1 9 7a n d7 0 3c o m p a r e dt ot h a to ft h e
untreated sample which was at a value of 131 (Figure 5A). Statistical
analysis of the histograms showed the percentage of cells positive for
CB[7]N4 staining as an average of 5% for untreated cells, 24% for a
concentration of 3.2 mM, and 86% for 32 mM( F i g u r e5 B ) .
To determine the intracellular stability of the CB[7]N4
complex we conducted a time course assay. CB[7]N4 was
incubated with the cells for 20 min and then chased for 15, 45,
and 120 min. This resulted in high MFIs of 743 after 15 min
chase, 612 after 45 min, and 544 after 120 min chase time in
o n er e p r e s e n t a t i v ee x p e r i m e n t( Figure 5C). Further analysis
determined that the percentage of cells positive for staining was
6% for untreated cells, 92% after 15 min chase, 91% after
45 min and finally 85% after a chase time of 120 min. This
indicated that the CB[7]N4 complex has significant intracellular
stability for at least 120 min.
Co-localization assays using fluorescence microscopy was
conducted using Dextran-647, and CB[7]N5 in order to analyze
the intracellular localization of the container. Dextran-647 was
incubated with cells at a concentration of 125 mg/mL overnight to
stain cell lysosomes. Cells were then pulsed with CB[7]N5 for
20 min and chased for 15, 45, 120 min. This analysis showed an
initial uptake of CB[7]N5 and Dextran-647 at 15 min with little co-
localization (Figure 6A) however at 45 min, an increase in CB[7]
co-localization with Dextran-647 was observed (Figure 6B).
Figure 2. HEK293 toxicology assays. The assay was performed using CB[7], CB[5], 1, 2, and 3 which indicated high cell tolerance of all containers
up to a concentration of 1 mM. MTS (A) and AK assays (B) performed after the cells had been incubated with indicated containers and drugs for two
days (UT = Untreated, C= Camptothecin, E= Erythromycin, EE= Erythromycin Estolate). AK assay was conducted using supernatant from cells
seeded for the MTS assay. This and all other figures are representative of three replicate experiments. Statistical analysis for all figures used unpaired
t-test analysis with *P=0.01–0.05; **P=0.001–0.01; ***P,0.001.
doi:10.1371/journal.pone.0010514.g002
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previously used to demonstrate the uptake of CB[7] by mouse muscle
embryo cells (NIH/3T3) via immunofluorescence microscopy[47]. In
addition, a CB[6] loaded with a FITC-spermine conjugate was
created and shown to be internalized by HepG2 cells[48]. Both of
these studies did not quantify the uptake of the container nor did they
investigate its intracellular localization but nevertheless they demon-
strated that othercelltypes besidesthe macrophagesused inourstudy
are able to take up CB[n] containers. As a whole the results of all of
these studies strongly suggests that many complexes of CB[n]-type
containers are able to cross the cell membrane. This ability for CB[7]
complexes to cross cell membranes is of course critical if CB[n]-type
molecular containers are to be used for drug delivery.
M. smegmatis treatment with EMB and the CB[7]NEMB
Complex
Finally, we wanted to assess what effect the loading of a drug
into CB[7] would have on the bioactivity of the drug. We used M.
smegmatis, a non-virulent mycobacterium, as a model for in vitro
infections of macrophages. Ethambutol (EMB) is a widely used
antituberculosis drug that has been associated with drug resistance
in M. tuberculosis [35,37,49]. RAW264.7 cells were infected with M.
smegmatis and then treated with EMB and CB[7]NEMB for 3 days
and the amount of viable bacteria was determined (Figure 7). At
day 3, untreated cells provided high bacterial survival with a CFU
of 1.24610
7 (65.4610
6) CFU/mL. At a MIC of 0.1 units, cells
treated with EMB resulted in 4610
5 (62.3610
5) CFU/mL and
Figure 3. HepG2 toxicology assays using various containers. This assay showed high cell viability and low toxicity. HepG2 MTS (A) and AK (B)
assays were conducted using the procedure described in Fig 2.
doi:10.1371/journal.pone.0010514.g003
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5
(66610
5) CFU/mL. CFU values between EMB and CB[7]NEMB
at a MIC value of 0.4 units were found to be 3.6610
4
(61.7610
3) CFU/mL and 4.3610
4 (61.7610
3) CFU/mL respec-
tively. At a MIC of 0.8 units, EMB was 1610
3 (64610
2) CFU/
mL and CB[7]NEMB was 6610
2 (63.3610
2) CFU/mL. Finally at
a MIC of 1 units, CFU values for EMB and CB[7]NEMB were
8610
2 (66.6610
2) CFU/mL and 1.4610
3 (61.1610
3) CFU/mL
respectively. The values of CFUs within each MIC dose for free
EMB or CB[7]NEMB were not significantly different from each
other (unpaired t-test) indicating no inhibition of the container on
the ability of the drug to kill the bacteria (Figure 7).
Previously, the Kim group loaded the anticancer drug,
oxaliplatin into CB[7] and showed that the cytotoxic activity of
the drug was reduced by 5–10 fold depending on which cancer
cell line was used as a target [20]. In contrast, no to moderate
decrease of activity upon loading into CB[7] has been reported
for a dinuclear platinum complex [50]. The latter finding could
be confirmed in an in vivo cancer model using Balb/c mice
bearing human ovarian cancer [51]. Thus it seems that potential
inhibitory effects of loading drugs into CB[7] have to be
determined for each individual drug however overall there is
good evidence that a variety of guest drug molecules will not
significantly decrease in bioactivity upon binding to CB[7]
containers.
Materials and Methods
Materials and Instruments
Trypsin/EDTA, Dextran-Alexa647, and ProlongH Gold Anti-
fade Agent were purchased from Invitrogen. Erythromycin,
erythromycin estolate and Hoechst33342 were purchased from
Sigma-Aldrich. Camptothecin was obtained from Calbiochem.
Instruments used included Spectramax M5e (Molecular Devices),
Leica SP5 X Confocal, and BD FACSCanto II.
Cell and Bacterial Culture
RAW264.7 cells (Mouse leukaemic monocyte macrophage,
ATCC #TIB-71) and HEK 293 cells (Human Embryonic
Kidney, ATCC #CRL-1573) were grown in DMEM (GIBCOH)
media (Invitrogen) with 10% heat inactivated fetal calf serum
(FCS) (Hyclone), 2% HEPES (Invitrogen), and 1% Penicillin/
Streptomycin (Invitrogen). HepG2 (Heptacellular carcinoma,
Human, ATCC #HB-8065) were grown in MEM media
(Sigma) with 10% FCS, 2% HEPES, and 1% Penicillin/
Streptomycin. M. smegmatis was cultured as described in
Velmurugan et al [52].
CB[n] Synthesis and Labeling with Fluorophores
Cucurbit[n]urils CB[7], CB[5], pentamer 1, and FITC-
spermine conjugate 4 were synthesized according to the published
procedures [12,24,25]. The synthesis and recognition properties of
compounds 2 and 3 will be reported separately [23].
Compound 1-(1-adamantyl)piperazine. A mixture of 1-
bromoadamantane (2.00 g, 9.29 mmol) and piperazine (4.80 g,
55.7 mmol) were heated at 210uC in a pressure tube for 16 h. The
reaction mixture was cooled to RT and dissolved in CHCl3
(60 mL). The organic layer was washed with 0.1 M NaOH
(2625 mL) and brine (2625 mL) then concentrated. The crude
solid was dissolved in EtOH (30 mL) followed by the addition of
conc. HCl. After concentration, the solid was washed with EtOH
(10 mL), centrifuged, the supernatant decanted, and the solid
dried under high vacuum yielding 1-(1-adamantyl)piperazine
dihydrochloride (1.66 g, 6.46 mmol, 69%) as an off-white solid.
M.p. 299–301uC. IR (KBr, cm
21): 3456s, 3412s, 2920s, 2854s,
2712s, 2481s, 2423s, 1445 m, 1364s, 896 m, 650 m.
1H NMR
(400 MHz, D2O): 3.57 (br. m, 8H), 2.27 (s, 3H), 1.99 (s, 6H), 1.75
(d, J=12.0, 3H), 1.67 (d, J=12.0, 3H).
13C NMR (100 MHz,
CDCl3): 67.2, 41.9, 41.4, 36.0, 35.0, 29.7.
Compound 5. A stock solution (4.1 mM) of 4.06 mg 1-(1-
adamantyl)piperazine in sodium bicarbonate buffer solution
(4.5 mL, 100 mM, pH=8.30) was prepared. A portion of this
stock solution (0.234 mL, 9.6610
27 mol) was added to 1.0 mg
(8.0610
27 mol) of the Alexa Fluor 555 carboxylic acid NHS ester
(Invitrogen, Cat. #20009). The solution was stirred at room
temperature for 1 h and then concentrated under high vacuum to
yield 5 which was used without further purification. Compound 5
Figure 4. RAW264.7 toxicology assays using CB[7]. These results
signified high cell tolerance at concentrations of up to 1 mM of CB[7].
RAW264.7cells were incubated with the CB[7] and camptothecin for
two days before conducting both MTS (A) and AK (B) assays. Both
assays were conducted following the procedure indicated in Fig 2.
doi:10.1371/journal.pone.0010514.g004
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50 mM, pH=7.22).
CB[7] Complexes. Complexes CB[7]N4 and CB[7]N5 were
prepared separately by dissolving CB[7] (0.44 mg, 0.32 mmol) in
the stock solutions of 4 (0.2 mL, 1.6 mM) or 5 (0.2 mL, 1.6 mM)
in sodium phosphate buffer (50 mM, pH=7.22) at room
temperature. The CB[7]Nethambutol complex was prepared by
dissolving equimolar amounts of CB[7] and ethambutol in sodium
phosphate buffer (50 mM, pH=7.22) at room temperature.
Cell Viability and Toxicity Assays
Cells were seeded in 96-well microtiter plates (Corning) at a
concentration of 2.5610
6 cells/mL for HEK293 cells,
4610
5 cells/mL for HepG2 cells and 8610
4 cells/mL for
RAW264.7 cells in 200 mL/well. After 24 hours, the HEK293
and RAW264.7 cells were treated with camptothecin (500 nM),
erythromycin, erythromycin estolate, CB[7], CB[5], 1, 2,o r3 at
10 mM, 100 mM, and 1 mM each. Six technical replicates were
designated for untreated cells and four technical replicates were
Figure5.CB[7]N4uptakeandintracellularstabilityofCB[7] in RAW264.7cells.Boththedosetitration andtimecourseassays usedRAW264.7cells
incubated with CB[7]N4 for 20 mins prior to analysis. (A) Dose titration assay used CB[7]N4 concentrations of 3.2 (green) and 32 mM (red). (B) Statistical
analysis of the percentage of cells positive for fluorescence. (C) Timecourse assay was conducted using 32 mMo fC B [ 7 ] N4. After incubation with the
fluorescent container, cells werechasedfor15(green), 45 (red)and120 min (blue)(D)Statisticalanalysisofthepercentageofcells positive forfluorescence.
doi:10.1371/journal.pone.0010514.g005
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erythromycin estolate and each of the five containers. We used the
CellTiter 96 AQueous KitH assay (Promega), an MTS-based
assay, to quantify cell viability by measuring cellular metabolism.
As a complementary assay we used the adenylate kinase (AK)
release assay, ToxilightHBioAssay (Lonza), to quantify necrotic cell
death. Both assays were performed according to the instructions
provided by the vendor after 48 h of incubation. The supernatant
from the samples used in the MTS assay were used in the AK
assay.
The collected absorbance and relative luminescence data were
normalized to percent cell viability (MTS) and percent cell death
(AK) using equations 1 and 2:
% cell viability ~ Abssample

AverageAbsUT

6 100 ð1Þ
% cell death ~ RLUsamples

Average RLUcamptothecin=Distilledwater

6 100
ð2Þ
Uptake Assay
RAW264.7 cells were seeded in a 24 well plate (Corning) at
5610
5 cells/mL. All samples were done in technical quadruplets and
then combined to form doublets per sample. Controls included
untreated cells and cells treated with 4 alone. The CB[7]N4 complex
was incubated with cells at the respective concentrations for 20
minutes and then collected for analysis. Cellswerecollected and fixed
with 4% paraformaldehyde (PFA) (Fisher), in PBS (MediaTech Inc)
before analysis by flow cytometry.
For the time course assay, CB[7]N4 was again incubated with
cells for 20 min. at a concentration of 32 mM after which time the
cells were washed and incubated for 15, 20, 120 min. with
infection medium (DMEM, and 10% FCS) before analysis by flow
cytometry.
Figure 6. Intracellular localization of CB[7] in RAW264.7 cell. Cell incubated with Dextran-647 and CB[7]N5 showed intracellular localization of
CB[7] through the endosomal pathway. RAW264.7cells were incubated with Dextran-647 (green) overnight and CB[7]N5 (red) for 20 min the following
day. Cells were chased for 15 (A), 45 (B) and 120 min (not shown) after incubation with CB[7]N5. Arrows indicate co-localization.
doi:10.1371/journal.pone.0010514.g006
Figure 7. M. smegmatis treatment using the TB drug, EMB, and
CB[7]. EMB loaded CB[7] (CB[7]NEMB, white bars) was equally effective
in treating M. smegmatis infected RAW264.7 cells as free EMB (patterned
bars). RAW264.7cells were incubated with M. smegmatis for two hours
and then chased for three days with EMB and CB[7]NEMB. Varying MIC
values for EMB and CB[7]NEMB were used: 0.1, 0.4, 0.8, and 1 units.
Viable bacteria were quantified using CFU/ml. This figure is represen-
tative of two replicate experiments.
doi:10.1371/journal.pone.0010514.g007
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RAW264.7 cells were seeded at 10
4 cells/well in 3-well glass
slides (Electron Microscopy Sciences). Controls included cells
stained with Hoechst33342 staining alone, Dextran-647 alone and
CB[7]N5 alone. Dextran-647 was incubated with cells overnight at
a concentration of 125 mg/mL. The CB[7]N5 complex was
incubated with cells for 20 min. at a concentration of 32 mM the
following day and then chased with infection medium for 15, 45,
and 120 min. Before analysis, cells were fixed with 4% PFA,
washed and immobilized with ProlongH Gold Antifade Agent
(Invitrogen).
Mycobacterial Killing Assay
RAW264.7 cells were seeded at 5610
5 cells/mL in one well of a
24-well plate. As controls we examined untreated cells on day 0
and day 3. Each sample was tested in technical duplicates. Cells
were infected with M. smegmatis at a multiplicity of infection (MOI)
of 10:1 for 2 h and then incubated with chase media (infection
media with varying concentrations of EMB or CB[7]NEMB) for 3
days. The EMB and CB7NEMB were used at minimum inhibitory
concentration (MIC) values of 0.1 (2.4 mM), 0.4 (9.6 mM), 0.8
(19.2 mM) and 1 (24 mM) [53] units during M. smegmatis treatment.
On day 3, cells were lysed with 1 ml/well of distilled water/
0.05%Tween-80. The cell lysate for each condition was added to
7H9 (DifcoH Middlebrook) media. These solutions were then
serially diluted four times and plated in technical triplicates of
5 mL each on 7H10 (DifcoH Middlebrook) agar plates. Viable
bacteria were quantified by calculating the number of colony
forming units (CFU) per mL.
Statistical Analysis
Statistical analysis of data was performed using the unpaired t-
test at 95% confidence interval (*P=0.01–0.05; **P=0.001–0.01;
***P,0.001). All data were plotted using mean 6 SEM excluding
Figure 6 which was graphed with mean 6 SD. For all
experiments, one representative figure out of at least three
independent experiments is shown unless indicated otherwise.
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